Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2019 | Induction in myeloma: a journey over time

Mohamad Mohty • 15 Jun 2019
EHA 2019
Multiple Myeloma Bortezomib Carfilzomib Daratumumab Dexamethasone Isatuximab Thalidomide
CASSIOPEIA

Induction therapy regimens prior to transplant in multiple myeloma have changed significantly over the past several decades, as explained by Mohamad Mohty, MD, PhD, of Saint-Antoine Hospital, Paris, France. Prof. Mohty gives us his insight into this change and where we may be going next. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Mohamad Mohty

Myeloma updates from EHA 2022: the DETERMINATION trial, the role of transplant, and exciting novel immunotherapies
Mohamad Mohty et al. • 15 Jul 2022
Optimizing conditioning regimens for SCT in AML and MDS 3:38
Optimizing conditioning regimens for SCT in AML and MDS
Mohamad Mohty • 31 Mar 2025
Optimizing anti-CD38 monoclonal antibody-based quadruplet therapies in newly diagnosed myeloma 4:28
Optimizing anti-CD38 monoclonal antibody-based quadruplet therapies in newly diagnosed myeloma
Mohamad Mohty • 31 Mar 2025
Looking forward to the upcoming COMy 2025 meeting 1:05
Looking forward to the upcoming COMy 2025 meeting
Mohamad Mohty • 31 Mar 2025

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals